Naptumomab estafenatox

Naptumomab estafenatox
Naptumomab estafenatox ?
Monoclonal antibody
Type Fab fragment
Source Mouse
Target 5T4
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 676258-98-3 N
ATC code None
UNII 93T929W6LC N
Chemical data
Formula C3255H5025N855O1050S18 
Mol. mass 73.5 kDa
 N(what is this?)  estafenatox (verify)

Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma[1] and renal cell carcinoma[2].

Schematic image of naptumomab estafenatox.
VH, VL: variable (antigen binding) domains of antibody fragment
CH1, CL: constant domains of antibody fragment
SAg: superantigen SEA/E-120

Mechanism of action

Chemically, it is a fusion protein consisting of the antigen-binding fragment (Fab) of a monoclonal antibody with the superantigen staphylococcal enterotoxin E (SEA/E-120, "estafenatox").[3] The Fab binds to 5T4, an antigen expressed by various tumor cells, and the superantigen induces an immune response by activating T lymphocytes.

See also

References

  1. ^ Borghaei, H; Alpaugh, K; Hedlund, G; Forsberg, G; Langer, C; Rogatko, A; Hawkins, R; Dueland, S et al. (2009). "Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer". Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27 (25): 4116–23. doi:10.1200/JCO.2008.20.2515. PMC 2734423. PMID 19636016. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2734423. 
  2. ^ ClinicalTrials.gov
  3. ^ WHO Drug Information
v · d · eMonoclonal antibodies for tumors
Tumor ("-t(u[m])-")
Human ("-tumu-")

Adecatumumab • Belimumab • Cixutumumab • Conatumumab • Daratumumab • Drozitumab • Figitumumab • Ganitumab • Glembatumumab vedotin • Intetumumab • Iratumumab • Lexatumumab • Lucatumumab • Mapatumumab • Narnatumab • Necitumumab • Ofatumumab • Olaratumab • Panitumumab • Pritumumab • Radretumab • Rilotumumab • Robatumumab • Teprotumumab • Votumumab • Zalutumumab

"-melu-" (melanoma): Flanvotumab
Mouse ("-tumo-")

Altumomab pentetate • Anatumomab mafenatox • Arcitumomab • Bectumomab • Blinatumomab • CC49 • Detumomab • Ibritumomab tiuxetan • Minretumomab • Mitumomab • Moxetumomab pasudotox • Naptumomab estafenatox • Nofetumomab merpentan • Pemtumomab† • Pintumomab • Racotumomab • Satumomab pendetide • Taplitumomab paptox • Tenatumomab • Tositumomab • 3F8

"-govo-" (ovarian tumor): Abagovomab • Igovomab • Oregovomab

"-pro-" (prostate tumor): Capromab pendetide

"-colo-" (colonic tumor): Edrecolomab • Nacolomab tafenatox
Chimeric ("-tuxi-")

Amatuximab • Bavituximab • Brentuximab vedotin • Cetuximab • Ensituximab • Girentuximab • Indatuximab ravtansine • Rituximab • Siltuximab • Ublituximab

"-mexi-" (melanoma): Ecromeximab
Humanized ("-tuzu-")
Afutuzumab • Alemtuzumab • Bevacizumab • Bivatuzumab mertansine • Cantuzumab mertansine • Cantuzumab ravtansine • Citatuzumab bogatox • Clivatuzumab tetraxetan • Dacetuzumab • Dalotuzumab • Elotuzumab† • Etaracizumab • Farletuzumab • Ficlatuzumab • Gemtuzumab ozogamicin • Inotuzumab ozogamicin • Labetuzumab • Lintuzumab • Lorvotuzumab mertansine • Matuzumab§ • Milatuzumab • Nimotuzumab • Onartuzumab • Oportuzumab monatox • Pertuzumab • Sibrotuzumab • Tacatuzumab tetraxetan • Tigatuzumab • Trastuzumab • Tucotuzumab celmoleukin • Veltuzumab
Rat/mouse hybrid ("-tumaxo-")


Stub icon This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.